Stereotactic Magnetic Resonance Guided Radiation Therapy

Launched by DANA-FARBER CANCER INSTITUTE · Oct 2, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of radiation therapy called Stereotactic Magnetic Resonance Guided Radiation Therapy (SMART) for patients with various types of cancer, including pancreatic, lung, and kidney cancers, among others. The goal is to find out how safe and effective this treatment is, particularly in controlling tumors and improving patients' quality of life. The study is divided into two parts: the first part will focus on how well the treatment can be given to patients safely, and the second part will measure how well it works in treating their cancer.

To be part of this trial, participants must be at least 18 years old and have a confirmed cancer diagnosis that requires this type of radiation therapy. They should have tumors that are 7 centimeters or smaller and be in good enough health to understand and agree to participate. Participants will undergo treatment and regular check-ups to monitor their health and the effects of the therapy. It's important to note that pregnant women and individuals with certain medical conditions, like severe anxiety about MRI machines, may not be eligible. Overall, this study aims to provide valuable information that could help improve cancer treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.
• • Tumor size ≤ 7cm
• • Age 18 years of older.
• • ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
• • Ability to understand and the willingness to sign a written informed consent document.
• • Specific eligibility requirements for each disease site with be covered in each specific cohort.
• Exclusion Criteria:
• • Specific exclusion requirements for each disease site with be covered in each specific cohort
• • History of allergic reactions attributed to gadolinium-based IV contrast.
• • -- Note: If a patient will not receive contrast, this is not applicable
• • Pregnant women are excluded from this study.
• • Severe claustrophobia or anxiety
• • Participants who cannot undergo an MRI